Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jeremy W. Jacobs(Vanderbilt University), Brian D. Adkins(University of Virginia Health System), Evan M. Bloch(Johns Hopkins University), Minh‐Ha Tran(University of California, Irvine), María Eva Mingot‐Castellano(Hospital Universitario Virgen del Rocío), Landon M. Clark(Vanderbilt University), Thomas C. Binns(Yale University), Garrett S. Booth(Vanderbilt University Medical Center), Sheharyar Raza(University of Toronto), Deva Sharma(Vanderbilt University Medical Center), Kenneth J. Moise(Dell Children's Medical Center of Central Texas), Bipin N. Savani(Vanderbilt University Medical Center), Elizabeth Abels(The University of Texas Medical Branch at Galveston), Zoe McQuilten, Ross M. Fasano(Emory University), Eleni Gavriilaki(Aristotle University of Thessaloniki), Miriam Andrea Duque(University of Miami), Christopher A. Tormey(Yale University)
Cited by 15
Related Papers
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863
A Literature Review of Zika Virus
|Emerging infectious diseases|2016|615
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
|Bristol Research (University of Bristol)|2021|589
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
|Journal of Clinical Investigation|2020|480
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435